Orexo
10.3
SEK
-0.96 %
ORX
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
Be the first to follow this company
orexo.com/investors
Orexo is a Swedish pharmaceutical company that develops medicines based on proprietary formulation technologies that meet major medical needs. In the US market, Orexo offers treatment solutions for patients suffering from opioid addiction and related diseases. Products targeting other therapeutic areas are developed and commercialized worldwide in collaboration with partners. The head office, where the research and development work is conducted, is located in Uppsala.
Revenue
638.8M
EBIT %
-17.14 %
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
NASDAQ Stockholm
ORX
Daily low / high price
9.82 / 10.48
SEK
Market cap
357.52M SEK
Turnover
964.42K SEK
Volume
96K
Latest videos
Financial calendar
Annual report
2025-02-06
Interim report
2025-05-06
Interim report
2025-07-16
Interim report
2025-10-23
Annual report
2026-02-05
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Novo A/S | 27.8 % | 27.8 % |
Avanza Pension | 6.6 % | 6.6 % |
Arbejdsmarkedets Tillaegspension (ATP) | 5.1 % | 5.1 % |
Anders Walldov direct and indirect | 4.6 % | 4.6 % |
Swedbank Insurance | 2.8 % | 2.8 % |
Nordnet Pension Insurance | 1.6 % | 1.6 % |
Stefan Hansson | 1.3 % | 1.3 % |
Håkan Lejonkula | 1.2 % | 1.2 % |
Christer Nyström | 0.8 % | 0.8 % |
Nucleus Capital AB | 0.8 % | 0.8 % |
ShowingAll content types
Orexo Delårsrapport kv 3 2024
Orexo Interim Report Q3 2024
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools